Skip to main content
KYUNG NAM PHARM.CO.,LTD. logo

KYUNG NAM PHARM.CO.,LTD. — Investor Relations & Filings

Ticker · 053950 ISIN · KR7053950002 KO Manufacturing
Open in API
Filings indexed 428 across all filing types
Latest filing 2026-02-24 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 053950

About KYUNG NAM PHARM.CO.,LTD.

https://www.kyungnampharm.com:6519/eng/

Kyung Nam Pharm is a pharmaceutical company established in 1957 that specializes in over-the-counter (OTC) medicines and health functional foods. The company is widely known for its flagship brand, Lemona, which was the first powdered Vitamin C product in its domestic market and is now marketed as an inner-beauty product. The core product portfolio also includes PM, a topical treatment for athlete's foot, and Minol F Troche for sore throats. A key area of specialization is human placenta-based medicines; the company was a pioneer in developing and commercializing human placenta drink formulations. Kyung Nam Pharm focuses on developing accessible healthcare solutions based on its corporate philosophy of promoting human health.

Recent filings

Filing Released Lang Actions
주식병합결정
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement regarding a 'Stock Consolidation' (주식병합결정) by Kyungnam Pharm. It details the ratio of consolidation, the schedule for the shareholder meeting, trading suspension dates, and the purpose of the consolidation (stock price stabilization). This falls under capital structure changes, which is classified as 'Share Issue/Capital Change' (SHA).
2026-02-24 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Kyungnam Pharm. It outlines the date, time, location, and the agenda items (financial statement approval, articles of incorporation amendment, and director/auditor compensation limits). This is a standard proxy solicitation document used to inform shareholders of an upcoming meeting and the matters to be voted upon.
2026-02-24 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from a Korean company (Kyungnam Pharm) disclosing a significant change in financial results (revenue or profit/loss structure change of 30% or more). This is a standard regulatory disclosure requirement in the Korean market (DART system) for material financial events. Since it is a specific financial disclosure announcement rather than a full annual report or a simple report publication notice, it falls under the 'Regulatory Filings' category as the most appropriate fallback for this type of material event disclosure.
2026-02-20 Korean
전환가액의조정
Capital/Financing Update Classification · 1% confidence The document is a formal regulatory filing titled '전환가액의조정' (Adjustment of Conversion Price) for Kyungnam Pharm. It details the adjustment of the conversion price for convertible bonds, including the calculation method, the change in the number of convertible shares, and the effective date. This type of filing relates to capital structure changes and financial instruments, which falls under the 'Capital/Financing Update' category.
2026-02-10 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, including conversion price adjustments for convertible bonds, and identifies the reporting entity and special related parties. This falls under the 'Major Shareholding Notification' category.
2026-01-23 Korean
전환가액의조정
Regulatory Filings Classification · 1% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system regarding the 'Adjustment of Conversion Price' (전환가액의 조정) for convertible bonds. This type of filing details changes to the conversion price and the resulting number of shares, which directly impacts the company's capital structure. Since it is a specific regulatory announcement regarding capital structure changes (convertible debt) and does not fit into the other specific categories like 'Share Issue' or 'M&A', it is classified as a Regulatory Filing (RNS).
2026-01-22 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.